Physician profile
Emily K Nesbitt
NPI 1225667173
$3,080.83
in general payments reported to CMS, 2019-2025
23 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $160 · 2024: $1,227 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.07 |
| Education | $106.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.28 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $338.11 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $300.50 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $232.67 | 2024-2025 | Dupixent |
| Genzyme Corporation | $225.46 | 2024-2025 | |
| Janssen Biotech, INC. | $189.54 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $185.29 | 2025 | Nemluvio, Aklief |
| Ucb, INC. | $178.40 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $156.60 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $132.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.54 | 2024 | Spevigo |
| Amgen INC. | $86.72 | 2025 | Otezla, Otezla |
| Organon LLC | $77.89 | 2025 | Vtama |
| Incyte Corporation | $63.81 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $46.89 | 2025 | Taltz, Ebglyss |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $46.55 | 2025 | Adbry, Anzupgo |
| Botanix Sb INC | $33.10 | 2025 | Sofdra |
| Sun Pharmaceutical Industries INC. | $32.13 | 2024 | |
| Pfizer INC. | $31.83 | 2025 | |
| Convatec INC. | $24.17 | 2024 | |
| Mimedx Group, INC. | $21.89 | 2024 | |
| Almirall LLC | $20.34 | 2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.71 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Nesbitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.